Skip to content
Search our Site
Search our site
Search our site
My PD Journey
About the EPDA
Political affairs and policy
Resources and publications
All research papers
Search research papers
Surgery research papers
Low-frequency subthalamic nucleus stimulation in Parkinson's disease: A randomized clinical trial
The optimal contacts for 60-Hz stimulation were situated more ventrally than those for 130-Hz stimulation (P = 0.038). Under the respective optimal, single monopolar stimulation, 60 Hz provided superior efficacy over 130 Hz in improving the total Unified Parkinson's Disease Rating Scale motor score (P < 0.001) and the akinesia (P = 0.011) and axial motor signs (P = 0.012) subscores without compromising the therapeutic effect on tremor and rigidity.
15 February 2014
Effects of deep brain stimulation frequency on bradykinesia of Parkinson's disease
No clear relationship between stimulation frequency and movement frequency was discovered. In light of the findings, a wider range of stimulation frequencies should be examined, particularly lower frequencies. Most current theories of PD pathophysiology and DBS mechanisms of action fail to explain results of the kind demonstrated herein.
15 February 2014
Long-term Clinical Outcomes After Fetal Cell Transplantation in Parkinson's: Implications for the Future of Cell Therapy
The results from these 2 cases indicate that dopaminergic cell transplantation can offer very long-term symptomatic relief in patients with Parkinson disease and provide proof-of-concept support for future clinical trials using fetal or stem cell therapies.
12 February 2014
Long-term outcome of subthalamic nucleus DBS in Parkinson's: From the advanced phase towards the late stage of the disease?
This study confirms the long-term safety and efficacy of STN-DBS in PD. Nevertheless, the functionality of patients worsens over time, mainly for the onset and progression of levodopa-resistant and non-motor symptoms. The role of PD-subtype seems to be relevant in the long-term outcome.
10 February 2014
Progression and survival in Parkinson's disease with subthalamic nucleus stimulation
Results: The mean annual change based on baseline and last observation scores in individually matched groups was 0.97 (SD = 3.57) for the surgery group and 1.04 (SD = 3.33) for the controls and thus not significantly different, F(1, 104) = .21, P = 0.89. The long-term mortality was also similar in the two groups during long-term follow-up, hazard ratio = 1.76, CL 0.913.40, P = 0.091.
04 February 2014
Phonemic verbal fluency decline after STN DBS does not depend on number of microelectrode recordings or lead tip placement
Conclusions: Significant decline in phonemic verbal fluency did not correlate with surgical passes nor with location of the lead tip or active stimulation site. These data suggest that age may influence verbal fluency decline more than surgical technique.
03 February 2014
Deep brain stimulation in Parkinson's disease: meta-analysis of randomized controlled trials
Although the number of RCTs obtained is small, the total sample size is relatively large, confirming the efficacy of DBS in the control of motor signs and improvement of patients' functionality and quality of life. More controlled research is required on the neurocognitive and psychiatric effects of DBS.
02 February 2014
Urinary profile of catecholamines and metabolites in Parkinson patients with deep brain stimulation
Conclusion: After DBS-STN, the DA/l-DOPA ratio, an indirect measure of DA synthesis, increased. These results show that DBS-STN may improve the efficacy of oral levodopa.
01 February 2014
STN-DBS does not change emotion recognition in advanced Parkinson's disease
In a sample of 30 patients 6 had depression or apathy at baseline that significantly increased to 14 post-surgery. There were no significant changes in the tests of identity discrimination, discrimination of emotional faces, naming of emotional faces, recognition of emotional prosody, and naming of emotional prosody after STN-DBS. The results of emotion tests could not predict the development of the neuropsychiatric symptoms.
01 February 2014
Use of Genetically Modified Mesenchymal Stem Cells to Treat Neurodegenerative Diseases
The aim of this literature review is to provide insights into: (1) the inherent properties of MSCs as a platform for neurotrophic factor delivery; (2) the molecular tools available for genetic manipulation of MSCs; (3) the rationale for utilizing various neurotrophic factors for particular neurodegenerative diseases; and (4) the clinical challenges of utilizing genetically modified MSCs.
23 January 2014
Back to Top
Add page to PDF basket
Copyright © 2015 EPDA. All Rights Reserved.
Privacy and cookies